Loading…
← CockpitCompetitor Analysis › TARS Tarsus Pharmaceuticals, Inc.Open in the cockpit ↗

Tarsus Pharmaceuticals, Inc.TARSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Specialty eye-care pharma selling Xdemvy, the first approved treatment for Demodex blepharitis (eyelid mite infection).

Momentum strong 79
Mkt cap
$3.74B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$59.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.7%
Hurdle
-125 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$75.95
1D-2.9%
1W-1.1%
1M+6.9%
3M+6.2%
6M+17.2%
YTD-7.2%
1Y+2.4%
ATR %5.0%
Beta0.61
52w lowhigh17.0% off high

What Tarsus Pharmaceuticals does

Specialty eye-care pharma selling Xdemvy, the first approved treatment for Demodex blepharitis (eyelid mite infection).

Revenue comes almost entirely from Xdemvy, a prescription eye drop approved in 2023, so uptake depends on eye doctors prescribing it and insurers paying for it. A pipeline in other eye and skin conditions is still at the trial stage.

Products and services

  • Xdemvy (Demodex blepharitis)
  • Pipeline (Lyme disease, rosacea)

Customers

  • Ophthalmologists
  • Optometrists

Where it sits in the supply chain

  • Ophthalmology pharmaceuticals
  • Eye-care drug commercialization
  • Specialty sales force

What could go right

  • Xdemvy prescription growth/penetration
  • Pipeline expansion into new indications

What could go wrong

  • Reimbursement/payer coverage pushback
  • Single-product revenue concentration

Moat: narrow (IP / patents, regulatory licence). First and only approved Demodex blepharitis treatment, protected by patents and exclusivity.

Headquarters: Irvine, California, US · Founded: 2017 · Employees: 370

Named competitors

Tarsus Pharmaceuticals at a glance

Size Tarsus Pharmaceuticals (TARS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.74B, the 1380th largest of 3,085 United States companies the cockpit tracks. Shares closed at $75.95 on 18 Nov 2026.

Performance Over six months the shares gained 17.2%, against +3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 86.3% over the last twelve months (peer median +10.3%); the operating margin is -9.6% (peer median 18.9%).

Valuation It trades at 5.2× enterprise value to sales against a peer median of 4.2× (7th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +160%, so the hurdle is -125 pp: the price already allows for a slowdown.

Short interest Short interest is 12.3% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026TARS 120Peer median 104
Six months, rebased to 100: Tarsus Pharmaceuticals against the median of its 20 peers (local-currency closes).

Tarsus Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$682M$451M$183M$17.4M$25.8M
Revenue growth—+147%+949%-32%—
Gross profit$636M$421M$170M$15.9M$24.9M
EBITDA-$62.6M-$69.2M-$119M-$142M-$61.9M
Net income-$702M-$66.4M-$116M-$136M-$62.1M
Free cash flow$32.4M-$22.3M-$84.6M-$119M-$49.5M
Capital expenditure$17.5M$9.86M$6.57M$5.50M$506,000
Total debt$88.7M$83.0M$72.5M$31.7M$20.2M

Quarterly statements and history in the cockpit →

Tarsus Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%ROVI600329000513XENE688336SLSOGN3320128940WOCKPHARMADFTXSFZNACUTAAS1877ARQT002262AMLXTARS6-month return →1-month return →
Up and to the right = strong over both horizons. Tarsus Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×10×20×ROVI600329000513688336OGN6005213320301569WOCKPHARMAACUTAAS1877ARQTTARSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tarsus Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%ROVI600329000513688336301569WOCKPHARMAARQTTARSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tarsus Pharmaceuticals is the large dot.

Tarsus Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (TARS vs BLCO.TO vs ABBV vs HROW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Tarsus Pharmaceuticals TARS$3.74B+17%+86%-10%5.2×34.7%
Bausch + Lomb BLCO.TO$7.41B+35%+11%9%2.2×12.0%
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%
Harrow HROW$1.21B+4%+21%1%4.7×n/a
Alcon ALC.SW$36.9B+18%+1%12%3.9×12.2%

How Tarsus Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tarsus Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureTARSPeer medianRank in peer set
1-month return+6.9%-0.2%6th highest of 21
6-month return+17.2%+3.5%7th highest of 19
Distance from 52-week high-17.0%-26.4%8th highest of 21
Revenue growth (TTM)+86.3%+10.3%3rd highest of 18
Operating margin-9.6%18.9%2nd lowest of 16
EV / Sales5.2×4.2×7th most expensive of 16
Growth the price implies (Req g, 7 yrs)34.7%3.0%4th most demanding of 13
Growth delivered (Del g)+159.5%+6.7%2nd highest of 13
Hurdle (Req g minus delivered)-124.9 pp-7.0 pp2nd least demanding of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%5.1×16.2%-5.8%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%2.3×-9.6%+2.7%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%5.5×0.9%+45.1%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%27.6×57.4%+3.1%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%3.3×4.7%+7.5%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a

Questions

Who are Tarsus Pharmaceuticals's main competitors?
Named competitors: Bausch + Lomb (BLCO.TO), AbbVie (Allergan eyecare) (ABBV), Harrow (HROW), Alcon (ALC.SW). The cockpit's measured peer set (industry) also includes Laboratorios Farmaceuticos Rovi (ROVI.MC), Tianjin Pharmaceutical Da Ren Tang (600329.SS), Livzon Pharmaceutical (000513.SZ), Xenon Pharmaceuticals (XENE), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), SELLAS Life Sciences (SLS).
Is Tarsus Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 5.2× against a peer median of 4.2×, 7th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +160%, so the hurdle is -125 pp: the price already allows for a slowdown.
How has Tarsus Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +17.2% against +3.5% for the median peer; over one year +2.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.